Neurotech International (ASX: NTI)Share Price and News
About Neurotech International
Neurotech International is an Australian biotechnology company focused on developing and commercialising treatments for neurological and mental health conditions.
The company is primarily working on NTI164, a cannabis-derived therapy aimed at treating paediatric neurological disorders such as Autism Spectrum Disorder (ASD), PANDAS/PANS, Rett Syndrome, and spastic cerebral palsy. Preclinical and clinical studies have vindicated not just that it can work, but that it addresses the underlying causes and not just symptoms.
NTI Company History
Neurotech was founded with a vision to address critical gaps in the treatment of neurological and mental health disorders. It acquired a Malta-based company (AAT Research) that had Mente Autism, a home-based device to relax kids' minds and listed - events that occurred in 2016.
While Mente was approved by the TGA, things fell apart in 2019 when it turned out that the founder of AAT Research did not have a Doctorate of Philosophy in neuroscience and he was terminated. Mente's TGA registration was cancelled. NTI then pivoted to a unique cannabis strain that it thought could address autism (NTI-164). Now, it has expanded into Rett Syndrome, the same disorder Neuren is targeting.
Phase I/II results were positive in both indications and the company is now targeting a larger trial that could see it receive regulatory approval, in autism.
Future Outlook of Neurotech International (ASX: NTI)
Looking ahead, Neurotech International is well-placed to benefit from the need for efficacious neurological treatments. The company estimates it has a >US$10bn TAM across all indications and that's assuming conservative pricing and a mere 1% market share.
NTI is aiming for a provisional Australian determination and US Independent New Drug approval in the US by the end of 2025. It aims for TGA approval by the end of 2026, and for first revenues in 2027. Beforehand, the company hopes to have secured a partnering and/or licensing deal.
As good as this sounds, the company's fate is susceptible to regulators and the success of clinical trials. A lack of ability to stick with these timelines could be fatal to its future.
Is NTI a Good Stock to Buy?
Neurotech International presents an intriguing investment opportunity. It is attacking a neurological disorder (Rett) that made investors in Neuren rich, and it has the additional angle of bringing a medicinal cannabis drug to market.
However, when considering whether to buy NTI stock, there are several important factors to keep in mind. The most important of which is whether or not it can stay on track with its timelines.
NTI has significant growth potential, especially as its treatment moves closer to commercialisation, but it is also high risk.
Our Stock Analysis
Sorry, we couldn't find any posts. Please try a different search.
Frequently Asked Questions
Neurotech International does not currently offer a dividend, as it is focused on reinvesting earnings into its research and development efforts.